Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke
Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the p...
Uloženo v:
| Vydáno v: | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Ročník 124; číslo 8. Vyp. 2; s. 56 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | ruština |
| Vydáno: |
Russia (Federation)
2024
|
| Témata: | |
| ISSN: | 1997-7298 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the problem, taking into account the compensation of cardiovascular disorders, the elimination of neurological and psychopathological syndromes, the improvement of cerebral circulation and the use of neuroprotective agents that increase the resistance of brain tissue to hypoxia and ischemia. Insufficient clinical efficacy of neuroprotectors is due to a number of objective reasons, of which only two are universal. The first of these reasons is the timing of the start of therapy in the clinic, as a rule, is outside the «therapeutic window»; the second reason is the fact that disturbance of the patency of the cerebral vessels in the affected area makes it difficult or impossible to deliver the drug to the penumbra area. The way out of this situation is the intranasal route of drug administration, which is characteristic for the analogs of regulatory peptides such as for H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MGHPPGP). The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period. The clinical efficacy of MGHPPGP was shown both in atherothrombotic and cardioembolic subtypes of stroke, against the background of blood flow disturbances in both the carotid and vertebrobasilar systems. |
|---|---|
| AbstractList | Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the problem, taking into account the compensation of cardiovascular disorders, the elimination of neurological and psychopathological syndromes, the improvement of cerebral circulation and the use of neuroprotective agents that increase the resistance of brain tissue to hypoxia and ischemia. Insufficient clinical efficacy of neuroprotectors is due to a number of objective reasons, of which only two are universal. The first of these reasons is the timing of the start of therapy in the clinic, as a rule, is outside the «therapeutic window»; the second reason is the fact that disturbance of the patency of the cerebral vessels in the affected area makes it difficult or impossible to deliver the drug to the penumbra area. The way out of this situation is the intranasal route of drug administration, which is characteristic for the analogs of regulatory peptides such as for H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MGHPPGP). The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period. The clinical efficacy of MGHPPGP was shown both in atherothrombotic and cardioembolic subtypes of stroke, against the background of blood flow disturbances in both the carotid and vertebrobasilar systems.Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the problem, taking into account the compensation of cardiovascular disorders, the elimination of neurological and psychopathological syndromes, the improvement of cerebral circulation and the use of neuroprotective agents that increase the resistance of brain tissue to hypoxia and ischemia. Insufficient clinical efficacy of neuroprotectors is due to a number of objective reasons, of which only two are universal. The first of these reasons is the timing of the start of therapy in the clinic, as a rule, is outside the «therapeutic window»; the second reason is the fact that disturbance of the patency of the cerebral vessels in the affected area makes it difficult or impossible to deliver the drug to the penumbra area. The way out of this situation is the intranasal route of drug administration, which is characteristic for the analogs of regulatory peptides such as for H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MGHPPGP). The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period. The clinical efficacy of MGHPPGP was shown both in atherothrombotic and cardioembolic subtypes of stroke, against the background of blood flow disturbances in both the carotid and vertebrobasilar systems. Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases of the circulatory system and in the overall mortality of the population. Successful treatment of CVD involves an integrated approach to the problem, taking into account the compensation of cardiovascular disorders, the elimination of neurological and psychopathological syndromes, the improvement of cerebral circulation and the use of neuroprotective agents that increase the resistance of brain tissue to hypoxia and ischemia. Insufficient clinical efficacy of neuroprotectors is due to a number of objective reasons, of which only two are universal. The first of these reasons is the timing of the start of therapy in the clinic, as a rule, is outside the «therapeutic window»; the second reason is the fact that disturbance of the patency of the cerebral vessels in the affected area makes it difficult or impossible to deliver the drug to the penumbra area. The way out of this situation is the intranasal route of drug administration, which is characteristic for the analogs of regulatory peptides such as for H-Met-Glu-His-Phe-Pro-Gly-Pro-OH (MGHPPGP). The review of clinical studies indicates that MGHPPGP is clinically effective in the treatment of ischemic stroke both in the acute period of stroke and in the recovery period. The clinical efficacy of MGHPPGP was shown both in atherothrombotic and cardioembolic subtypes of stroke, against the background of blood flow disturbances in both the carotid and vertebrobasilar systems. |
| Author | Fedorov, V N Spirin, N N Vdovichenko, V P |
| Author_xml | – sequence: 1 givenname: N N orcidid: 0000-0001-9078-589X surname: Spirin fullname: Spirin, N N organization: Yaroslavl State Medical University, Yaroslavl, Russia – sequence: 2 givenname: V N orcidid: 0009-0003-1296-1861 surname: Fedorov fullname: Fedorov, V N organization: Yaroslavl State Medical University, Yaroslavl, Russia – sequence: 3 givenname: V P orcidid: 0009-0009-6739-6154 surname: Vdovichenko fullname: Vdovichenko, V P organization: Educational Institution Grodno State Medical University, Grodno, Belarus |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39166935$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1UMtOwzAQ9KGIltIvQEI-cjH4kdjxEVXQIIHaA5wjJ9kQlyQOsQvK35NCOaxmVzMazewFmnWuA4SuGL1lijF5t-_ga3Cc8ojxiCY8ljO0YFororhO5mjl_Z5SyhKWSCnP0VxoJqUW8QKNu8YUgF2FXWPfXQ99sCXglLxAIJvmQFLrya4GshvcdI-_uE2x7XCo4TiD6UdsuhIPUJvcNjaYYF13tOynDbrg8bcNNba-qKG1BfZhcB9wic4q03hYnXCJ3h4fXtcped5untb3z6RgigYiI0i4yBMqQFZlFZsil3GkdFSZmFdJERWCAYDSxUQmSkRiakp5lUsjdS4UX6KbP99-cJ8H8CFrpyTQNKYDd_CZoDqWKo6VnqTXJ-khb6HM-sG2Zhiz_3fxH--pby4 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.17116/jnevro202412408256 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Mesto oligopeptida H-Met-Glu-His-Phe-Pro-Gly-Pro-OH v terapii i reabilitatsii patsientov s ishemicheskim insul'tom |
| ExternalDocumentID | 39166935 |
| Genre | Journal Article English Abstract Review |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF NPM W2D 7X8 |
| ID | FETCH-LOGICAL-c170t-64e823b803e6fdf5acb654794fa52f8c4c31eee79cdf58734300002fb6a69b372 |
| IEDL.DBID | 7X8 |
| ISSN | 1997-7298 |
| IngestDate | Thu Jul 10 23:46:02 EDT 2025 Thu Jan 02 22:30:10 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8. Vyp. 2 |
| Keywords | cerebrovascular diseases oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH ischemic stroke neuroprotectors |
| Language | Russian |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c170t-64e823b803e6fdf5acb654794fa52f8c4c31eee79cdf58734300002fb6a69b372 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0009-0003-1296-1861 0009-0009-6739-6154 0000-0001-9078-589X |
| PMID | 39166935 |
| PQID | 3095675579 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3095675579 pubmed_primary_39166935 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-00-00 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – year: 2024 text: 2024-00-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Russia (Federation) |
| PublicationPlace_xml | – name: Russia (Federation) |
| PublicationTitle | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova |
| PublicationTitleAlternate | Zh Nevrol Psikhiatr Im S S Korsakova |
| PublicationYear | 2024 |
| SSID | ssj0001818666 |
| Score | 2.268556 |
| SecondaryResourceType | review_article |
| Snippet | Cerebrovascular diseases (CVDs) are one of the leading causes of death and disability In Russia: they rank second in the structure of mortality from diseases... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 56 |
| SubjectTerms | Administration, Intranasal Humans Ischemic Stroke - drug therapy Neuroprotective Agents - administration & dosage Neuroprotective Agents - therapeutic use Oligopeptides - therapeutic use Stroke Rehabilitation - methods |
| Title | Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and rehabilitation of patients with ischemic stroke |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39166935 https://www.proquest.com/docview/3095675579 |
| Volume | 124 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhx3xcieA3ONGmTnEREncuMPSjMbWg2LUoztjPC_Hvz2g7iQRC8pJTQUvJek-9t30Po0tCAiiXvEWWFIywyGZGxDKYKN1xqJ63Sqm42wYdDMRrJtHW4VW1a5WJPrDdq4zX4yK8oMObxOObyevJBoGsURFfbFhrLqEMDlAGt5iPx7WOp6dzqAiMgHQ04UrTEQ7wHOV6F_Sx9sP6hAzOYSsnvMLM-bu43__uhW2ijBZr4ptGMbbRUznbQ2qANpe-ieQoOdOwd9u_5i59AdouxuE8Gdkoe3mekn1ckfbUkLX24n9fXxz7OCxwwI27qtuY4Kwwuf7B9wytbttYKg5sX58GChhx8XE1L_2b30PP93dNtn7R9GIju8e6UJMyKiCrRpTZxxsWZVtCyWDKXxZETmmnas9YG2YZJwSmjcApGTiVZIhXl0T5aKXxhDxHWzplIOKMVUyzrhoF1HeMiSwIwTIw4QheLRR0HPYfgRVZYP6vG38t6hA4ayYwnDSHHGIqHE0nj4z88fYLWQeKNF-UUdVz4y-0ZWtWf07wqz2sFCuMwHXwBQObQ-g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Place+of+oligopeptide+H-Met-Glu-His-Phe-Pro-Gly-Pro-OH+in+the+therapy+and+rehabilitation+of+patients+with+ischemic+stroke&rft.jtitle=Zhurnal+nevrologii+i+psikhiatrii+imeni+S.S.+Korsakova&rft.au=Spirin%2C+N+N&rft.au=Fedorov%2C+V+N&rft.au=Vdovichenko%2C+V+P&rft.date=2024-01-01&rft.issn=1997-7298&rft.volume=124&rft.issue=8.+Vyp.+2&rft.spage=56&rft_id=info:doi/10.17116%2Fjnevro202412408256&rft_id=info%3Apmid%2F39166935&rft_id=info%3Apmid%2F39166935&rft.externalDocID=39166935 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1997-7298&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1997-7298&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1997-7298&client=summon |